17家破亿，最高单笔5亿元！盘点2025年生物制造十大融资，国资深度参与！

Core Insights - The biomanufacturing sector is poised for significant growth by 2025, driven by strategic investments from state-owned enterprises and leading public companies, establishing a solid foundation for industry capital [1][2] - Funding trends indicate a shift from early-stage R&D to capacity expansion and commercialization, with a notable increase in financing activities across the sector [2] Financing Events - In January 2025, Liying Biotechnology secured nearly 100 million yuan in Series A funding led by Tianshui Bay Technology [3] - In February 2025, Ruide Lin Biotechnology completed over 500 million yuan in Series C funding, marking the largest single financing event in the biomanufacturing sector for the year [6] - In March 2025, Zhongke Guosheng raised 200 million yuan in A+ round funding, with participation from CITIC Jinshi and PwC Capital [7][8] - In August 2025, Yixi Biotechnology completed nearly 200 million yuan in Series A funding, focusing on the production of human milk oligosaccharides [9][11] - In December 2025, Tangzhi Pharmaceutical raised over 100 million yuan, with investments from AstraZeneca and other funds, focusing on nucleotides and sugar science products [16] Industry Trends - The biomanufacturing industry is experiencing a collective confidence boost, as evidenced by 17 companies achieving financing close to or exceeding 100 million yuan in 2025 [2] - The overseas market is also thriving, with leading companies securing over $320 million in funding within a year, particularly in the fermented protein food sector [4] - Companies like Colossal Bioscience are pushing the boundaries of biotechnology, having raised significant funds to pursue ambitious projects such as reviving extinct species [17]